EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Mesenchymal Stem Cell Therapy for Neurological Complications of Prematurity: A Narrative Review

Hua Hannah Yep, Jennifer H Bae iD, George A Wen iD, Sangel Gomez, Alexandra Tsivitis iD, Robert P Moore iD, Helen Hsieh iD, Sergio D Bergese iD

Pharmaceuticals · 12.03.2026 · 19 (3) · 464

DOI: 10.3390/ph19030464 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 12.03.2026. Verfasst von Hua Hannah Yep und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Stony Brook University Hospital, Stony Brook, NY 11794, USA. Die Arbeit nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Preterm birth is a leading cause of neonatal mortality and long-term disability worldwide. Injury in premature infants is demonstrated by disrupted organ development from inflammation, oxidative stress, hypoxia, and impaired vascular maturation. Current therapies largely provide supportive care and do not directly promote tissue regeneration. Mesenchymal stem cell (MSC)-based therapies have emerged as a potential strategy to enhance endogenous repair across organ systems commonly affected by prematurity.

Results

Evidence indicates that MSCs exert therapeutic effects primarily through transient paracrine signaling rather than long-term engraftment. Following administration, MSCs release cytokines, growth factors, and extracellular vesicles that reduce inflammation, promote angiogenesis, and support tissue repair. In preclinical models of neonatal brain injury, MSC therapy has been associated with improved oligodendrocyte maturation and reduced white matter injury. Early clinical trials in neonatal encephalopathy demonstrate feasibility and short-term safety of both autologous and allogeneic cell products. However, studies remain limited by small sample sizes and short follow-up. Cell-free approaches using MSC-derived extracellular vesicles may offer similar biological benefits with potentially lower safety and regulatory concerns.

Conclusions

MSC-based therapies represent a promising regenerative approach for complications of prematurity. Rigorous, large-scale trials with standardized protocols and long-term follow-up are necessary to clarify efficacy, optimize delivery strategies, and define safety in this vulnerable population.

Schlagwörter

Stichwörter der Autor:innen

encephalopathy of prematurityextracellular vesicleshit and runmesenchymal stem cellsneonatepre-termstem cell therapy

Autor:innen und Institutionen

  • Department of Anesthesiology, Stony Brook University Hospital, Stony Brook, NY 11794, USA.
  • Renaissance School of Medicine, Stony Brook University, Stony Brook, NY 11794, USA.
  • Department of Surgery, Stony Brook University Hospital, Stony Brook, NY 11794, USA.

ORCID-Profile: Jennifer H Bae, George A Wen, Alexandra Tsivitis, Robert P Moore, Helen Hsieh, Sergio D Bergese

Zitieren

APA

Yep, H. H., Bae, J. H., Wen, G. A., Gomez, S., Tsivitis, A., Moore, R. P., Hsieh, H., & Bergese, S. D. (2026). Mesenchymal Stem Cell Therapy for Neurological Complications of Prematurity: A Narrative Review. Pharmaceuticals, 19(3), 464. https://doi.org/10.3390/ph19030464

Vancouver

Yep HH, Bae JH, Wen GA, Gomez S, Tsivitis A, Moore RP, et al. Mesenchymal Stem Cell Therapy for Neurological Complications of Prematurity: A Narrative Review. Pharmaceuticals. 2026;19(3):464. doi:10.3390/ph19030464

BibTeX
@article{Yep2026,
  author = {Yep, Hua Hannah and Bae, Jennifer H and Wen, George A and Gomez, Sangel and Tsivitis, Alexandra and Moore, Robert P and Hsieh, Helen and Bergese, Sergio D},
  title = {Mesenchymal Stem Cell Therapy for Neurological Complications of Prematurity: A Narrative Review},
  journal = {Pharmaceuticals},
  year = {2026},
  volume = {19},
  number = {3},
  pages = {464},
  doi = {10.3390/ph19030464}
}
Kostenlos starten →